European Journal of Immunogenetics (1994), **21**, 553–557

AUTHOR INDEX

ABRAHAM, L.J., *see* LEELAYUWAT, C.
AL DACCAK, R., *see* MERCIER, B.
AL-HARBI, S., *see* FOUAD, F.
AL-HARBI, S., FOUAD, F. & KAABA, S.A. The first HLA anthropological study in the Kuwaiti population 295
ALBERT, E.D., *see* BODMER, J.G.
ALBERT, E.D., *see* DONDI, E.
ALDENER-CANNAVÁ, A. & OLERUP, O. *HLA-DQB1* 'low-resolution' typing by PCR amplification with sequence-specific primers (PCR-SSP) 447
ALKARMI, T.O., *see* FOUAD, F.
ALVAREZ MARTÍNEZ, V., *see* SETIÉN BARANDA, F.
AMAKI, I., *see* BANNAI, M.
AMARO, R., *see* BALDUCCI-SILANO, P.L.
ANDERSSON, L., *see* DAVIES, C.J.
ÁRNASON, A., SKAFTADÓTTIR, I., SIGMUNDSSON, J., MOONEY, E., BJÖRNSSON, J., CARIGLIA, N., PÁLSSON, G. & GUDJÓNSSON H. The association between coeliac disease, dermatitis herpetiformis and certain HLA-antigens in Icelanders 457
ARNAUD, J., *see* THOMSEN, M.
ARRIENS, M.A., *see* DAVIES, C.J.
ARRIENS, M.A., *see* DAVIES, C.J.
ARRIENS, M.A., *see* DAVIES, C.J.
ARRIENS, M.A., *see* DAVIES, C.J.
ASHDOWN, M.L., *see* NAUGHTON, M.J.

BACON, L.D., *see* PHARR, G.T.
BALDINI, G., *see* CARCASSI, C.
BALDUCCI-SILANO, P.L., LAYRISSE, Z., DOMINGUEZ, E., AMARO, R., GUNCZLER, P., LANES, R. & ZARO, R. HLA-DQA1 and DQB1 allele and genotype contribution to IDDM susceptibility in an ethnically mixed population 405
BANNAI, M., TOKUNAGA, K., LIN, L., KUWATA, S., MAZDA, T., AMAKI, I., FUJISAWA, F. & JUJI, T. Discrimination of human HLA-DRB1 alleles by PCR-SSCP (single-strand conformation polymorphism) method 1
BARBA, G.M.R., BRAUN-HEIMER, L., RITTNER, C. & SCHNEIDER, P.M. A new PCR-based typing of the Rodgers and Chido antigenic determinants of the fourth component of human complement
BARTON, C.H., *see* MOCK, B.A.
BAUR, M., *see* THOMSEN, M.
BERNOCO, D., *see* DAVIES, C.J.
BESTER, J., *see* DAVIES, C.J.
BESTER, J., *see* DAVIES, C.J.
BIDWELL, J.L. *DRB*, *DQA*, *DQB* and *DPB* nucleotide sequences of *Sanguinus oedipus* B95-8 67
BIDWELL, J.L., *see* DAY, S.
BIDWELL, J.L., LU, P., WANG, Y., ZHOU, K., CLAY, T.M. & BONTROP, R.E. *DRB*, *DQA*, *DQB* and *DPB* nucleotide sequences of *Sanguinus oedipus* B95-8 67
BISSUMBHAR, B., *see* DAVIES, C.J.
BISSUMBHAR, B., *see* DAVIES, C.J.
BJÖRNSSON, J., *see* ÁRNASON, A.
BLACKWELL, J., *see* MOCK, B.A.
BODMER, J.G., *see* KRAUSA, P.
BODMER, J.G., *see* MARSH, S.G.E.
BODMER, J.G., MARSH, S.G.E., ALBERT, E.D., BODMER, W.F., DUPONT, B., ERLICH, H.A., MACH, B., MAYR, W.R., PARHAM, P., SASAZUKI, T., SCHREUDER, G.M.TH., STROMINGER, J.L., SVEJGAARD, A. & TERASAKI, P.I. Nomenclature for factors of the HLA system, 1994 485
BODMER, W.F., *see* BODMER, J.G.
BONTROP, R.E., *see* BIDWELL, J.L.
BONTROP, R.E., *see* SLIERENDREGT, B.L.
BOROT, N., *see* THOMSEN, M.
BRAUN-HEIMER, L., *see* BARBA, G.M.R.
BROWNING, M.J., *see* KRAUSA, P.
BYRD, L.G., *see* MOCK, B.A.
BYRNS, G., *see* DAVIES, C.J.
BYRNS, G., *see* DAVIES, C.J.

CAMBON-THOMSEN, A., *see* THOMSEN, M.
CAMPBELL, D.A., NELSON, S., MADHOK, R., FIELD, M. & GALLAGHER, G. TNF NCO-I RFLP is not an independent risk factor in rheumatoid arthritis 461
CARCASSI, C., COTTONI, F., FLORIS, L., LA NASA, G., MULARGIA, M., BALDINI, G., SENES, G., ORRU, S., MONTESU, M.A., CERIMELE, D. & CONTU, L. The HLA-DRB1*0101 allele is responsible for HLA susceptibility to lichen ruber planus 425
CARIGLIA, N., *see* ÁRNASON, A.
CARTA, A., *see* MERCIER, B.
CASSIMAN, J.-J., *see* VANDEVYVER, C.
CASSIMAN, J.-J., *see* VANDEVYVER, C.
CERIMELE, D., *see* CARCASSI, C.
CERIOTTI, G., *see* DAVIES, C.J.
CHARLES, I., *see* MOCK, B.A.
CHARRON, D., *see* LEPAGE, V.

CHARRON, D., *see* MERCIER, B.
CHIN, H., *see* MOCK, B.A.
CHRISTIANSEN, F.T., *see* MARTINEZ, O.P.
CLAY, T.M., *see* BIDWELL, J.L.
CLAY, T.M., *see* DAY, S.
CONTU, L., *see* CARCASSI, C.
CORTESE HASSETT, A.L., *see* RUSHTON, J.J.
COTO, E., *see* SETIÉN BARANDA, F.
COTTONI, F., *see* CARCASSI, C.
CRACCO, P., *see* MERCIER, B.
CUCCIA, M., *see* DONDI, E.

DAHLÉN, G.H. Indications of an autoimmune component in LP(a) associated disorders 301
DARKE, C., *see* FUSSELL, H.
DARKE, C., *see* JAHN, I.
DARKE, C., *see* YOUNG, N.T.
DAVID, F., *see* MERCIER, B.
DAVIES, C.J., JOOSTEN, I., ANDERSSON, L., ARRIENS, M.A., BERNOCO, D., BISSUMBHAR, B., BYRNS, G., VAN EIJK, M.J.T., KRISTENSEN, B., LEWIN, H.A., MIKKO, S., MORGAN A.L.G., MUGGLI-COCKETT, N.E., NILSSON, PH.R., OLIVER, R.A., PARK, C.A., VAN DER POEL, J.J., POLLI, M., SPOONER, R.L. & STEWART, J.A. Polymorphism of bovine MHC class II genes. Joint Report of the Fifth International Bovine Lymphocyte Antigen (BoLA) Workshop, Interlaken, Switzerland, 1 August 1992 259
DAVIES, C.J., JOOSTEN, I., BERNOCO, D., ARRIENS, M.A., BESTER, J., CERIOTTI, G., ELLIS, S., HENSEN, E.J., HINES, H.C., HORIN, P., KRISTENSEN, B., LEWIN, H.A., MEGGIOLARO, D., MORGAN, A.L.G., MORITA, M., NILSSON, PH.R., OLIVER, R.A., ORLOVA, A., ØSTERGÅRD, H., PARK, C.A., SCHUBERTH, H.-J., SIMON, M., SPOONER, R.L. & STEWART, J.A. Polymorphism of bovine MHC class I genes. Joint Report of the Fifth International Bovine Lymphocyte Antigen (BoLA) Workshop, Interlaken, Switzerland, 1 August 1992 239
DAVIES, E.J., *see* DONN, R.P.
DAVIS, W.C., *see* NILSSON, PH.R.
DAWKINS, R.L., *see* LEELAYUWAT, C.
DAWKINS, R.L., *see* MARTINEZ, O.P.
DAY, S., RAYMOND, P.A., CLAY, T.M., WOOD, N.A.P. & BIDWELL, J.L. DR7-Dw17 and DR7-DwDB1 haplotypes contain different alleles of the HLA-DRB7 pseudogene 383
DEGLI-ESPOSTI, M.A., *see* LEELAYUWAT, C.
DODGSON, J.B., *see* PHARR, G.T.
DOMINGUEZ, E., *see* BALDUCCI-SILANO, P.L.
DONDI, E., CUCCIA, M., KELLER, E., MARTINETTI, M., LARIZZA, D. & ALBERT, E.D. Molecular analysis of CYP21 gene mutations carried on HLA-B14 positive haplotypes 341
DONN, R.P., DAVIES, E.J., THOMSON, W., HILLARBY, M.C. & OLLIER, W.E.R. TA gene associations in UK Caucasoids 159
DRISTENSEN, B., *see* DAVIES, C.J.
DUFOSSE, F., *see* MERCIER, B.
DUPONT, B., *see* BODMER, J.G.

ELLIS, S.A. MHC studies in domestic animals 207
ELLIS, S., *see* DAVIES, C.J.
ELLIS, S., *see* DAVIES, C.J.
ENCZMANN, J., *see* UHRBERG, M.
ERLICH, H.A., *see* BODMER, J.G.
EXCOFFIER, L., *see* GRUNDSCHOBER, C.

FEREC, C., *see* MERCIER, B.
FIELD, M., *see* CAMPBELL, D.A.
FLORIS, L., *see* CARCASSI, C.
FOUAD, F., *see* AL-HARBI, S.
FOUAD, F., JOHNY, K., KAABA, S., ALKARMI, T.O., SHARMA, P. & AL-HARBI, S. MHC in systemic lupus erythematosus: a study on a Kuwaiti population 11
FUJISAWA, F., *see* BANNAI, M.
FUSSELL, H., THOMAS, M., STREET, J. & DARKE, C. Serological identification of new HLA-B7 variant antigen — HLA-B7QUI 23

GALLAGHER, G., *see* CAMPBELL, D.A.
GARCÍA, A., *see* YÉLAMOS, J.
GARCÍA-LOZANO, J.R., *see* YÉLAMOS, J.
GARRED, P., HARBOE, M., OETTINGER, T., KOCH, C. & SVEJGAARD, A. Duel role of mannan-binding protein in infections: another case of heterosis? 125
GESERICK, G., *see* JAHN, I.
GEUSENS, P., *see* VANDEVYVER, C.
GILL, T.J., III, *see* RUSHTON, J.J.
GONZÁLEZ, M.F., *see* YÉLAMOS, J.
GROSSE-WILDE, H., *see* KUBENS, B.S.
GRUNDSCHOBER, C., SANCHEZ-MAZAZ, A., EXCOFFIER, L., LANGANEY, A., JEANNET, M. & TIERCY, J.-M. HLA-DPB1 DNA polymorphism in the Swiss population: linkage disequilibrium with other HLA loci and population genetic affinities 143
GUDJÓNSSON, H., *see* ÁRNASON, A.
GUNCZLER, P., *see* BALDUCCI-SILANO, P.L.

HAØASA, J., *see* KACPRZAK-BERGMAN, I.
HARBOE, M., *see* GARRED, P.
HAUPTMANN, G., *see* JAHN, I.
HENSEN, E.J., *see* DAVIES, C.J.
HENSEN, E.J., *see* DAVIES, C.J.
HILLARBY, M.C., *see* DONN, R.P.
HINES, H.C., *see* DAVIES, C.J.
HINES, H.C., *see* DAVIES, C.J.
HOBART, M.J., *see* ORREN, A.
HORIN, P., *see* DAVIES, C.J.
HORIN, P., *see* DAVIES, C.J.

IVANOVA, R., *see* LEPAGE,V.

JAHN, I., MEJÍA, J.E., THOMAS, M., DARKE, C., SCHRÖDER, H., GESERICK, G. & HAUPTMANN, G. Genomic analysis of the F subtypes of human complement factor B 415
JEANNET, M., *see* GRUNDSCHOBER, C.
JOHNY, K., *see* FOUAD, F.
JOOSTEN, I., *see* DAVIES, C.J.
JOOSTEN, I., *see* DAVIES, C.J.
JOOSTEN, I., *see* DAVIES, C.J.
JOOSTEN, I., *see* DAVIES, C.J.
JUJI, T., *see* BANNAI, M.

KAABA, S.A., *see* AL-HARBI, S.
KAABA, S., *see* FOUAD, F.
KACPRZAK-BERGMAN, I. & HAØASA, J. Gm and Km phenotype frequencies in children with chronic active hepatitis (CAH) B virus infection 373
KASAHARA, K., *see* OZAWA, T.
KATO, Y., *see* OZAWA, T.
KELLER, E., *see* DONDI, E.
KHALIL, I., *see* LEPAGE, V.
KOCH, C., *see* GARRED, P.
KONDO, N., *see* OZAWA, T.
KOSKIMIES, S., *see* WESTMAN, P.
KRALL, M.M., *see* MOCK, B.A.
KRAUSA, P., BROWNING, M.J., MOSES, J.H. & BODMER, J.G. HLA-LA locus DNA typing of the 4AOH cell panel by ARMS PCR 199
KRISTENSEN, B., *see* DAVIES, C.J.
KRISTENSEN, B., *see* DAVIES, C.J.
KRISTENSEN, B., *see* DAVIES, C.J.
KUBENS, B.S., PÄBLER, M. & GROSSE-WILDE, H. Detection efficacy of soluble HLA-A, B antigens using 1D-IEF 469
KUNZ, H.W., *see* RUSHTON, J.J.
KUWATA, S., *see* BANNAI, M.

LA NASA, G., *see* CARCASSI, C.
LACHMANN, P.J., *see* ORREN, A.
LANES, R., *see* BALDUCCI-SILANO, P.L.
LANGANEY, A., *see* GRUNDSCHOBER, C.
LANGÖ, A. & LINDBLOM, B. HLA DQA-DQB haplotypes in a Swedish population 453
LARIZZA, D., *see* DONDI, E.
LAYRISSE, Z., *see* BALDUCCI-SILANO, P.L.
LEELAYUWAT, C., DEGLI-ESPOSTI, M.A., TAYLOR, E., ABRAHAM, L.J. & DAWKINS, R.L. PCR SSCP reveals haplotype related polymorphism of PERB1: a new marker for MHC β block typing 431
LEIRISALO-REPO, M., *see* WESTMAN, P.
LEPAGE, V., SCHAEFFER, V., MALLET, C., IVANOVA, R., KHALIL, I. & CHARRON, D. Determination of DRB alleles using PCR amplification and allele-specific primers 45
LEWIN, H.A., *see* DAVIES, C.J.
LEWIN, H.A., *see* DAVIES, C.J.
LEWIN, H.A., *see* DAVIES, C.J.
LEWIN, H.A., see DAVIES, C.J.
LIEW, F.Y., *see* MOCK, B.A.
LIMM, T.M., *see* NAUGHTON, M.J.
LIN, L., *see* BANNAI, M.
LINDBLOM, B., *see* LANGÖ, A.
LOISEAU, P., *see* MERCIER, B.
LÓPEZ-LARREA, C., see SETIÉN BARANDA, F.
LU, P., *see* BIDWELL, J.L.

MACH, B., *see* BODMER, J.G.
MADHOK, R., *see* CAMPBELL, D.A.
MALLET, C., *see* LEPAGE, V.
MARSH, S.G.E. & BODMER, J.G. HLA class II region nucleotide sequences, 1994 519
MARSH, S.G.E., *see* BODMER, J.G.
MARTINETTI, M., *see* DONDI, E.
MARTINEZ, O.P., WITT, C.S., TAY, G., CHRISTIANSEN, F.T. & DAWKINS, R.L. Immunogenetic analysis of successful and rejected bone marrow grafts within one family 365
MARTÍNEZ-NAVES, E., *see* SETIÉN BARANDA, F.
MAYR, W.R., *see* BODMER, J.G.
MAZDA, T., *see* BANNAI, M.
MEGGIOLARO, D., *see* DAVIES, C.J.
MEJÍA, J.E., *see* JAHN, I.
MENÉNDEZ DIAZ, J., *see* SETIÉN BARANDA, F.
MERCIER, B., AL DACCAK, R., SAMAAN, A., DAVID, F., CARTA, A., CRACCO, P., RAGUENES, O., DUFOSSE, F., FEREC, C., CHARRON, D. & LOISEAU, P. HLA-DRB and -DQB typing by PCR amplification using sequence-specific primers (PCR-SSP): assessment after 1 year of routine use by three laboratories 105
MIKKO, S., *see* DAVIES, C.J.
MIKKO, S., *see* DAVIES, C.J.
MISRA, D.N., *see* RUSHTON, J.J.
MOCK, B.A., KRALL, M.M., BYRD, L.G., CHIN, H., BARTON, C.H., CHARLES, I., LIEW, F.Y. & BLACKWELL, J. The inducible form of nitric oxide synthase (*NOS2*) isolated from murine macrophages maps near the nude mutation on mouse chromosome 11 231
MONTESU, M.A., *see* CARCASSI, C.
MOONEY, E., *see* ÁRNASON, A.
MORENO, I., *see* YÉLAMOS, J.
MORGAN, A.L.G., *see* DAVIES, C.J.
MORITA, M., *see* DAVIES, C.J.
MOSES, J.H., *see* KRAUSA, P.
MOTOYOSHI, F., *see* OZAWA, T.
MUGGLI-COCKETT, N.E., *see* DAVIES, C.J.
MUGGLI-COCKETT, N.E., *see* DAVIES, C.J.
MULARGIA, M., *see* CARCASSI, C.

NAUGHTON, M.J., LIMM, T.M., ASHDOWN, M.L. &

SIMONS, M.J. DPB1 locus PCR-RFLP typing of the fourth Asia-Oceania histocompatibility workshop cell panel reveals a novel DPB1 allele 351
NELSON, S., *see* CAMPBELL, D.A.
NEUGEBAUER, M., *see* THOMSEN, M.
NILSSON, PH.R., *see* DAVIES, C.J.
NILSSON, PH.R., VAN'T KLOOSTER, J., VAN DER POEL, J., DAVIS, W.C. & SCHREUDER, G.M.T. Complexity of the bovine MHC class-II specificity DW3 as defined by alloantisera 169

OETTINGER, T., *see* GARRED, P.
OLERUP, O., see ALDENER-CANNAVÁ, A.
OLIVER, R.A., *see* DAVIES, C.J.
OLLIER, W.E.R., *see* DONN, R.P.
ORII, T., *see* OZAWA, T.
ORLOVA, A., *see* DAVIES, C.J.
ORLOVA, A., *see* DAVIES, C.J.
ORREN, A., WURZNER, R., LACHMANN, P.J. & HOBART, M.J. A novel human complement component C7 phenotype detected in South Africa and proposed designation of the allele as C7*10 181
ORRU, S., *see* CARCASSI, C.
ØSTERGÅRD, H., *see* DAVIES, C.J.
OZAWA, T., KONDO, N., KATO, Y., MOTOYOSHI, F., SUZUKI, Y., SHIMOZAWA, K., KASAHARA, K. & ORII, T. A wild-type μs C-terminal gene is expressed in Bloom's syndrome cells 133

PÁLSSON, G., *see* ÁRNASON, A.
PARHAM, P., *see* BODMER, J.G.
PARK, C.A., *see* DAVIES, C.J.
PARTANEN, J., *see* WESTMAN, P.
PÄBLER, M., *see* KUBENS, B.S.
PHARR, G.T., BACON, L.D. & DODGSON, J.B. A class I cDNA from SPAFAS line-11 chickens 59
PHILIPPAERTS, L., *see* VANDEVYVER, C.
POLLI, M., *see* DAVIES, C.J.
POLLI, M., *see* DAVIES, C.J.

RAGUENES, O., *see* MERCIER, B.
RAUS, J., *see* VANDEVYVER, C.
RAUS, J., *see* VANDEVYVER, C.
RAUS, P., *see* VANDEVYVER, C.
RAYMOND, P.A., *see* DAY, S.
RITTNER, C., *see* BARBA, G.M.R.
ROMERO, M., *see* YÉLAMOS, J.
RUSHTON, J.J., MISRA, D.N., KUNZ, H.W., CORTESE HASSETT, A.L. & GILL, T.J., III. Genomic structure and organization of a *Q*-like gene in the *GRC-G/C* region of the rat 189

SAMAAN, A., *see* MERCIER, B.
SÁNCHEZ, B., *see* YÉLAMOS, J.
SANCHEZ-MAZAZ, A., *see* GRUNDSCHOBER, C.
SASAZUKI, T., *see* BODMER, J.G.
SCHAEFFER, V., *see* LEPAGE, V.
SCHNEIDER, P.M., *see* BARBA, G.M.R.
SCHREUDER, G.M.T., *see* NILSSON, PH.R.
SCHREUDER, G.M.TH., *see* BODMER, J.G.
SCHRÖDER, H., *see* JAHN, I.
SCHUBERTH, H.-J., *see* DAVIES, C.J.
SENES, G., *see* CARCASSI, C.
SETIÉN BARANDA, F., COTO, E., MENÉNDEZ DIAZ, J., MARTÍNEZ-NAVES, E., ALVAREZ MARTÍNEZ, V. & LÓPEZ-LARREA, C. HLA class II and susceptibility and resistence to insulin-dependent diabetes mellitus in a population from the northwest of Spain
SEVIN, A., *see* THOMSEN, M.
SHARMA, P., *see* FOUAD, F.
SHIMOZAWA, K., *see* OZAWA, T.
SIGMUNDSSON, J., *see* ÁRNASON, A.
SIMON, M., *see* DAVIES, C.J.
SIMONS, M.J., *see* NAUGHTON, M.J.
SKAFTADÓTTIR, I., *see* ÁRNASON, A.
SLIERENDREGT, B.L. & BONTROP, R.E. Current knowledge on the major histocompatibility complex class II region in non-human primates 391
SPOONER, R.L., *see* DAVIES, C.J.
STEWART, J.A., *see* DAVIES, C.J.
STINISSEN, P., *see* VANDEVYVER, C.
STREET, J., *see* FUSSELL, H.
STROMINGER, J.L., *see* BODMER, J.G.
SUZUKI, Y., *see* OZAWA, T.
SVEJGAARD, A., *see* BODMER, J.G.
SVEJGAARD, A., *see* GARRED, P.

TAY, G., *see* MARTINEZ, O.P.
TAYLOR, E., *see* LEELAYUWAT, C.
TERASAKI, P.I., *see* BODMER, J.G.
THOMAS, M., *see* FUSSELL, H.
THOMAS, M., *see* JAHN, I.
THOMSEN, M., NEUGEBAUER, M., ARNAUD, J., BOROT, N., SEVIN, A., BAUR, M. & CAMBON-THOMSEN, A. Recombination fractions in the HLA system based on the data set 'Provinces Françaises': indications of haplotype-specific recombination rates 33
THOMSON, W., *see* DONN, R.P.
TIERCY, J.-M., *see* GRUNDSCHOBER, C.
TOKUNAGA, K., *see* BANNAI, M.

UHRBERG, M., ENCZMANN, J. & WERNET, P. Rapid DNA crossmatch analysis of HLA class II genotypic polymorphisms by temperature gradient gel electrophoresis in unrelated bone marrow donor selection 313

VAN DER POEL, J.J., *see* DAVIES, C.J.
VAN DER POEL, J., *see* NILSSON, PH.R.
VAN EIJK, M.J.T., *see* DAVIES, C.J.
VAN'T KLOOSTER, J., *see* NILSSON, PH.R.
VANDEVYVER, C., GEUSENS, P., CASSIMAN, J.-J. &

RAUS, J. T cell receptor delta locus polymorphism in rheumatoid arthritis 479
VANDEVYVER, C., RAUS, P., STINISSEN, P., PHILIPPAERTS, L., CASSIMAN, J.-J. & RAUS, J. Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis 377

WANG, Y., *see* BIDWELL, J.L.
WERNET, P., *see* UHRBERG, M.
WESTMAN, P., PARTANEN, J., LEIRISALO-REPO, M. & KOSKIMIES, S. HSP70-Hom NcoI polymorphism and HLA-associations in the Finnish population and in patients with ankylosing spondylitis or reactive arthritis 81
WITT, C.S., *see* MARTINEZ, O.P.
WOOD, N.A.P., *see* DAY, S.
WÜRZNER, R., *see* ORREN, A.

YÉLAMOS, J., GARCÍA-LOZANO, J.R., MORENO, I., ROMERO, M., GARCÍA, A. & SÁNCHEZ B. Frequency of HLA-DRB1 alleles in a Spanish population: their contribution to rheumatoid arthritis susceptibility 91
YÉLAMOS, J., GONZÁLEZ, M.F., GARCÍA-LOZANO, J.R. & SÁNCHEZ, B. Distribution of *HLA-A*28* alleles in a Spanish population 99
YOUNG, N.T. & DARKE, C. Gene frequency and linkage disequilibrium analysis of *HLA-DRB1*04* haplotypes in a South Wales population 15

ZERO, R., *see* BALDUCCI-SILANO, P.L.
ZHOU, K., *see* BIDWELL, J.L.

European Journal of Immunogenetics (1994), **21**, 558–564

SUBJECT INDEX

aetiologic fraction (δ) 221–26
agarose gel electrophoresis 48
allele nomenclature 485–517
allele-specific amplification *see* PCR-ASA
amplification
  HLA-DR, -DQB 114–21
  optimisation, HLA-DRB, -DQB allelic determination 111–13
  pseudogene 199–200
  two-step 4
  see also ARMS-PCR; primer
amplification refractory mutation system *see* ARMS-PCR
androgen excess 342
animal husbandry, and MHC studies 209–10
ankylosing spondylitis *see* AS
antibodies, Ch/Rg 326; *see also* mAb
antigen, self-mimicking 309
antigen capture, and sHLA identification resolution 469–77
antigen definition standards, class I, BoLA 242
antigen presentation, and TAP genes 159
antigenicity, reverse 327, 336
antisera, BoLA class II 263–4
4AOHW (Asia–Oceania Histocompatibility Workshop) 200, 351
apo (a) 301–2
  and Lp(a) plasma concentration 302
  polymorphism 301
apo B 301
Arg52 DQα 223, 225
ARMS-PCR 199–200
  advantages 203
  HLA-A locus 201–3
  limitations 164–5
  TAP gene study 164
arthritis, reactive *see* ReA
arthritis, rheumatoid *see* RA
AS (ankylosing spondylitis) 82, 88
  and B27 88–9
  HSP70 polymorphism 86
Asia–Oceania Histocompatibility Workshop, fourth *see* 4AOHW
atherogenicity 302, 307
atherosclerosis, and Lp(a) 303
ATP-binding family 159
autoimmune disease 91–2
  HLA 377
  infection 308–9
  see also orchitis; RA; ReA

B-F antigens 59
  B-L region 59, 60
  cDNA sequence listing 62–3
B-FL1-1 cDNA sequence listing 61
B-G proteins 59
B-L antigens 59, 60
band shifts, PCR-SSCP 5–6
β block matching 368–370
β sheet connecting loop 61
BF (complement factor B) 415
BF*F, genomic analysis 415–23
blood groups *see* Ch; Rg
Bloom's syndrome *see* BS
blot analysis 135–6, 191
  Nos2 study 232–3
BoLA (Bovine Lymphocyte Antigen) Workshop 169–70, 176, 210, 239–40, 260
  A16, and red cell antigens 249
  antisera, class II 263–4
  breed information 241–2
  novel genes
  – class I 243–4, 245, 246
  – class II 260
  w1/A34 245–6
  see also class I; class II; *specific haplotype under* HLA
bone marrow grafting, immunogenetic analysis 365–71
bootstrap resampling 147
bovine MHC 210
British Society for Histocompatibility and European Foundation for Immunogenetics meeting 387
BS (Bloom's syndrome) 134–8
  μs C-terminal segment 135, 136

C2 typing, PF material 34
C4 325–7
  allotyping 327–8
  isotypes 325; *see also* C4A; C4B
  RFLP analysis 343–345
C4A
  non-expressed gene detection 329, 332, 336, 337
  gene analysis 330
C4B
  and CYP21B 342
  gene analysis 330, 332
C4D region 327
C6
  deficiency 182–3
  rare phenotype 183, 185
C7 181
  deficiency 182–3
  M/N polymorphism 181
  M/N typing 185
  9IEF allotype 181
C7*10 182–6
  gene frequency 183
  segregation 184–5

CAH (congenital adrenal hyperplasia) 341–2
calcium and MBP 125
cattle
  class I conservation 253; *see also* BoLA
  MHC polymorphism 210; *see also* BoLA
Cchlb1, Chr11 linkage 233, 235
CD (coeliac disease) and HLA-DQ2 457-60
Ch blood group 325
  typing 330–2, 333, 334–5, 327–37
chicken, class I cDNA sequence 59–64
Chido blood group *see* Ch
Chlamydiae bacteria 309
clades, MHC 395–6
class I 391
  cattle 210–11
  DNA/serological typing comparison 200–3
  HSP70 peptide bonding groove 82
  novel genes, BoLA 243–246
  soluble
  – equine 212
  – ID-IEF 469–77
  typing
  – DNA approach 199–200; *see also* ARMS-PCR
  – pseudogenes 199–200
  see also BoLA
class I/II tissue typing, SLE 12–13
class I — class IIa haplotypes 281, 284
class II
  BoLA 282, 285–7
  bovine 211; *see also* BoLA
  DQA patterns, BoLA 271, 276–7
  DQB patterns 274, 278–9, 280
  DRB RFLP patterns, BoLA 270–1, 272–3
  gene registry 519–50
  human 391
  lineage age 393–4
  and Lp(a) 302
  non-human primates 391–9
  novel genes, BoLA 260
  polymorphism 391
  – analysis *see* TGGE
  subregion organization 397–9
  typing, non-human primates 392–3
class IIa BoLA 275, 283–5
class IIb BoLA 260, 282, 285
class III *see* HSP
cNOS (NO synthase) 231
codon 281, and 21-hydroxylase deficiency 346–9
coeliac disease *see* CD
complement component *see* C *complement number*
complement system, and MBP 126
complement typing, MUD grafting 366–7, 369
congenital adrenal hyperplasia *see* CAH
contamination, in typing 203
contig-mapping 398
coronary artery disease 303
cortisol biosynthesis 341–2
cosmid library, rat 189–90, 193
cross-amplification 111
cross-hybridization avoidance, and primers 107, 109
cross-over frequencies, and linkage disequilibria (PF) 35–6
cross-reactivity
  B7 (CREG) 23–4
  B7Qui 26–9
CYP21, and 21-hydroxylase deficiency 348
CYP21B gene 342–9
cytocidals 232–5
cytokine
  sex-linked 306
  and TNF 377

delta block matching 368–370
DH (dermatitis herpetiformis) 457–60
diabetes
  early onset, and Nos2 235
  streptozocin-induced 231
  see also IDDM
DIB haplotype 211, 282, 285, 286
disease
  and MHC polymorphism 391
  murine, and Nos2 232
  and polymorphism maintenance 130
  susceptibility 160, 166
disequilibrium, total 151, 153; *see also* linkage disequilibrium
DNA extraction 106
DNA typing/serology, for Rg/Ch typing 337
DOB haplotype 282, 285, 286
dot blot hybridization 344–5, 345–7
DRBF (D-region focusing) 170
Ds03
  antisera production 170–1, 171, 172–3
  reactivity discrimination 173
  Ds11 distinction 178
Dw2 specificity, BoLA 275
Dw3 169–70, 170

electrophoresis
  agarose gel 48
  and banding patterns 8
  polyacrylamide gel 353
electrophoretic mobility 1
epitope prediction 211
ethnic groups *see* population
Ewens–Watterson test 147, 148

FAP (family analysis package) 34–5
foam cell formation 307, 308
*Fok*I 353, 356
  problems 358

G/C region (rat) 189
gene registry
  DR7-Dw17/DwDB1 haplotypes 383–86
  HLA class II 519–550
  Sanguinis oedipus, DRB, DQA, DQB, DPB 67–76
generic typing, HLA-DQB1 447–55
genes
  bovine specific 211, 260
  protective (IDDM) 225
genetic distance 154
  HLA-DPB1 148–9
  Swiss HLA-DP 147
genomic cosmid library, rat 189–90, 193
genotyping, PCR-SSCP 2

geographic distance 154
HLA-DPB1 148–9
gluten sensitivity, and DH 457
Gm
Mongoloid population 374
and HBV infection 373–5

H chains 133
haplotype, 2-, 4-locus 146–7
haplotypes, extended, Swiss study 144–53
Hardy–Weinberg equilibrium 147
HBV (hepatitis B virus) infection 373–5
heat shock proteins *see* HSP
hepatitis B virus *see* HBV
hepatoma, and HBV 374
heteroduplex DNA formation 314
heterogeneity (Ds03), and lymphocyte absorption 173, 175
hitch-hiking effect 397
HLA
and genetic susceptibility to autoimmune disease 377
genetic/physical distances 36
Kuwaiti distribution 295–300
PCR-RFLP limitations 359
serological limitation 210
and SLE 11
also class I; class II
HLA antigens
MUD grafting 366–7, 369
SLE 12–13
HLA autoimmune disease, and TNF 377
HLA gene nomenclature 485–517
HLA lineage
evolution 393, 394–6
loss 395
HLA sequence databank 485–517
HLA system, and PF allelic differences study 34
HLA typing, TAP gene study 161
HLA-A
A frequency, Swiss 146, 148, 149
A locus, typing 201–3
Kuwaiti distribution 296–9
HLA-A-B haplotypes 150
HLA-A-B-DRB1-DPB1 haplotypes 152
HLA-A28 allele distribution (Spanish) 99-102
HLA-B
ancestral haplotypes 431–46
B frequency, Swiss 146, 147–8
CL profiles 367–8, 370
Kuwaiti distribution 296–9
lineage 431–46
on recombinant haplotypes 38
HLA-B-DR haplotypes 150
HLA-B-DRB1 haplotype 151
HLA-B7 23–4
B7 CREG 23–4
B7 cross-reactivity 26, 29
HSP-70 association 83–4, 86, 88
HLA-B7Qui
cross-reactivity 26–9
identification 23–9
segregation 25
HLA-B14 positive haplotype, and CYP21B gene 345–7
HLA-B14,DR1 haplotype, and CYP21B 342, 345–6, 348
HLA-B27 cross-reactivity 27, 29
HLA-B55
cross-reactivity 28, 29
HLA-DR4 association 20
HLA-B56 cross-reactivity 28, 29
HLA-B57/HSP70 association 87–8
HLA-B60 cross-reactivity 29
HLA Bw53 209
HLA-C, Kuwaiti distribution 298
HLA-D, chimpanzee 392
HLA-DP
polymorphism, and RA 93–6
primate 393, 397–9
see also DPA1; DPB1
HLA-DPA fragment patterns 360–1
HLA-DPB fragment patterns 360–1
HLA-DPB1
allele assignment 353, 354, 357
– complicated 356
DRB1 locus differences 154
frequency, Swiss 146, 148
genetic/geographic distance 148–9
hypervariable region 351
novel 351–63, 358
oligotyping 144–55
in RA 93–4
restriction enzyme digestion 353, 355
HLA-DQ
allele/molecule, in IDDM 405–14
cattle 211
and IDDM
– α/β 405–14
– distribution 221–6
– heterodimers 226
Kuwaiti distribution 298, 300
primate 392–3, 399
see also TAP genes
HLA-DQ1, protective role in oral LP 425
HLA-DQ2, and CD 457–60
HLA-DQA patterns, BoLA 271, 276–7, 282, 285
HLA-DQA1
and IDDM 405–14
typing, intron-based 363
HLA-DQB patterns 274, 278–9, 280, 285
HLA-DQB1
and IDDM 405–14
typing, low-resolution 447–55
HLA-DR
α/β chains 2
amplification results 114–21
crossmatch analysis, TGGE 317–9, 322
differentiation, TGGE 319–22
distribution, IDDM study 221–6
DPB1 linkage disequilibrium, and RA 93, 94, 95–6
DQ 170, 285, 286
fingerprinting, TGGE 317, 319, 321
gene frequencies, sex-linked 305–6
homoduplex pattern TGGE analysis 315, 315–6
Kuwaiti distribution 298, 299
and Lp(a) 304–7

PCR-SSCP 2–4
PF material frequency 39
primate 397–9
and RA 92
(non-)recombinant 37, 39
restriction fragment pattern 117–8
subtyping 113, 116
typing, rapid 45–57
typing accuracy 41
HLA-DR1, and LP 425–9
HLA-DR2
DRB1 analysis 6
frequency, recombinant haplotypes 41
and proteinuria 13
HLA-DR3
and DH 457–60
frequency, recombinant haplotypes 41
group analysis 7
and IDDM 295–6
and RA 296
HLA-DR3/DR4, and diabetes 220, 226–8
HLA-DR4
B55 association 20
frequency, recombinant haplotypes 41
group analysis 6–7
polymorphism, and HVR 15–6
HLA-DR7-Dw17 383–6
HLA-DR7-DwDB1 383–6
HLA-DR8 group analysis 7
HLA-DR11
frequency, recombinant haplotypes 41
group analysis 7
HLA-DR12 group analysis 7
HLA-DR13 group analysis 7
HLA-DR14 group analysis 7
HLA-DR52 group analysis 7
HLA-DRA genes (cattle) 211
HLA-DRB
cattle 211
group allele definition 48–56
phylogenic tree 395–6
RFLP patterns, BoLA 270–1, 272–3, 282, 285
typing ambiguities 55–6
UT (untranslated region) 395, 396
HLA-DRB1
analysis 6–7
frequency, Swiss 146–9
HLA-DRB1*04 analysis 15–20
HLA-DRB1-DPB1 haplotypes 150–2
HLA-DRB2-TM patterns, BoLA 271
HLA-DRB3
BoLA 262, 274–5, 280–1
TGGE distinguished 322
HLA-DRB3m BoLA 262
HLA-DRB7
polymorphism 383–6
sequence 385
HLA-DYA 211, 262, 282, 285, 286
HLA-DYB genes 211
HSP (heat shock proteins) 81
HSP70 polymorphism 83–6
HSP70-1 86–8
HSP70-2 86–8
HSP70-Hom 81–9
HVR (hypervariable regions), in HLA-DR4
polymorphism 15–6

ID–IEF, soluble HLA-A, -B antigens 469–77
IDDM (insulin-dependent diabetes mellitus) 219–20
and DQ molecule 405–14
HLA association 220
– class II (Spanish) 220–8
– DR3 295–6
– DQA1, -B1 405–14
negative haplotype association 227
population genetic variation 226–7
susceptibility markers 227, 228
'trigger' 219–20
see also diabetes; insulitis
IEF (isoelectric focusing) 170
aim of, fifth BoLA workshop 253
band-interval shift 184, 186
BoLA workshop 242–3, 249–54
C7 182–3
class I BoLA 242–3, 249–254
class II BoLA 261–2, 264, 270
interpretation 253–4
macaque DR 392
one dimensional *see* ID-IEF
soluble HLA-A, -B antigens 469–77
IEF-defined splits, BoLA workshop support 252
Ig (immunoglobulin)
concentrations, BS 134
isotypes 133
Ig A, and DH 457
IgM deficiency 134; *see also* BS
immune response
HLA class II 105
MBP 125
TNF 377–81
immunisation, Ds03 170–1, 176, 178
immunodeficiency *see* BS
immunoglobulin *see* Ig
Immunoglobulin Gene Expression in Development and Disease (conference) 205–6
inflammatory disease *see* LP
insulitis, and interleukin release 309
interferon determination 303
interleukin
and atherogenesis 308
determination 303
insulitis 309
International Conference on Animal Genetics, XXIV 79, 206
International Histocompatability Workshop
X, cell lines 107
XI
– sera 25
– specificities 145, 146
isoelectric focusing *see* IEF
one dimensional *see* ID-IEF

Khalil model 223, 225
Km phenotypes, and HBV infection 373–5
kringle domain 302
Kuwaiti

HLA haplotype 300
and SLE 11–14

lambda-exonuclease digestion of PCR products 5
left primers 46, 48–9
leishmaniasis, murine cutaneous, and Nos2 235
leprosy, and MBP 126–30
leukaemia, linkage disequilibrium 151, 153
lichen ruber planus *see* LP
ligand binding, MBP 126–7
ligase I controlling gene defect 138
lineage, HLA-B 431–46
linkage disequilibrium
cross-over frequencies 35–6
HLA-DQA1/DQB1/TAP2B 163
HLA-DRB1*04 18–20
TAP/class-II 163, 165
TAP1/TAP2 162
TAP2/HAL-DR, -DQ 165
TAP2D/DR4 164
liver, and Lp(a) synthesis 302
LP (lichen ruber planus) 425–9
and HLA-DRB1*0101 allele 425–9
oral, protective allele 425
Lp(a) 301
atherogenicity 302
atherosclerosis 303
class II genotype 302
HLA-DR 304–7
plasma concentration 302
RA 309–10
lymphocytes, Dw3 study 172, 173, 175

mAb (monoclonal antibodies)
BoLA class II 264
bovine class II 261
for immunoprecipitation 469–77
MAILA 172
W6/32, IEF results 249–51
MAILA assay 170, 172, 177, 178
malaria
and HLA Bw53 209
and MBP 128
mannan-binding protein *see* MBP
matched unrelated donor grafting *see* MUD
MBP (mannan-binding protein) 125–30
binding conditions 125
in leprosy 126–30
ligand binding 126–7
low concentration 126
malaria 128
mycobacteria 130
surgery 128
MHC
and bone marrow grafts 365
bovine
– alloantisera 169–70
– heterogeneity investigation 170–9
see also BoLA
caprine 213
complement factor B *see* BF
disease association 431–46
domestic animals 209–13
equine 212–3
evolutionary lineage 431–46
mouse/rat comparison 189
ovine 213
polymorphism
– origin 393
– trans-species evolution 393, 394–5
porcine 213
rat 190
sequences, and epitope prediction 211
see also class I; class II; HLA
MHC Class III *see* HSP
mimicry, molecular 309
MLC matching test 2
MS, and TNF 378–381
MUD (matched unrelated donor) grafting 365–6
CL allotyping 367–8, 370
delta block matching 368–70
HLA antigens 366–7
mutation
and BoLA class II 282
detection 1–2
and gene copies 396
(non-)synonymous 396
see also polymorphism
mycobacteria, and MBP levels 130
tuberculosis 127, 129

NCoI (restriction enzyme) 83
nitric oxide 231
NOS, inducible *see* Nos2
Nos2 232
Chr11 linkage 233, 235
nude mutation, and Nos2 233, 235

opsonic defects 125, 126; *see also* MBP
orchitis 88

PAGE 353
parasitic infection, and class-I phenotype 212
pathogens, and MHC polymorphism 209, 210
PCR 45
BF*F subtype determination 415–23
class-I genes (cattle) 210–11
class II 313–14
HLA-DR1 2–4, 15, 17–18
HLA-DRB, -DQB 109, 111
HSP-70 82-3
isotype-specific 328, 329–30
non-expressed C4A gene detection 329, 332, 336, 337
RA study 92–3
see also ARMS-PCR
PCR-ASA 45–57
characteristics 56
PCR–SSO concordance 56
PCR-RFLP 56
fragment patterns, 4AOHW panel 360–1
HLA-DPB1 locus 352–63
– complicated 356
– novel 356, 358
HLA-DRB, -DQB allelic determination 111
intron-based 363

limitations 359
PCR-SSCP 1–2
DR group 4–5
PERB1 431–46
PCR-SSO
IDDM study 220
PCR-ASA concordance 56
PCR-SSOP (sequence specific oligonucleotide probing) 16–18, 199
for HLA-DR4 typing 16, 18
limitations 18
PCR-SSP
low resolution, of HLA-DQB1 447–55
RFLP analysis concordance 122
RFLP matching compared, HLA-DQB1 447–55
technique 105–123
– advantages 113, 122
– method 106–111
peptide bonding, HLA Class I/HSP70 82
PERB1, polymorphism 431–46
PF (Provinces Françaises) survey 33–4
re-evaluated sample 34
plasma lipoprotein, human *see* Lp(a)
plasminogen/apo (a) similarities 301–2
platelets, Dw3 study 171, 174
polymorphism
in animal populations 210–11
bovine
– BoLA class II 285
– class-I 210–11
– class-II 211
C4 325–6
detection 1–2
and disease 391
HLA-DPB1 investigated 144–55
and HVR 15–16
maintenance, and disease 130
origin 393, 396–7; *see also* mutation
PERB1 431–46
protein charge 181
T cell receptor delta locus, and RA 479–83
TAP gene 160–1
population
and A28 allele distribution 101–2
Cape Coloured
– gene frequency 184–5
– genetic history 182
European, and HLA-DP haplotype 150–1
genetic distance 154
– HLA-DPB1 148–9
– Swiss HLA-DP 147
and HLA distribution 299–300
and IDDM genetic variation 226–7
SLE suceptibility 12–13
Swiss, genetic comparison 148–9, 154–5
pregnancy, and MHC expression, equine 212–3
primates, MHC class II subregion organization 397–9
primers
cross-amplification 111
CYP21B gene 343, 344
HLA-A28 100
HLA-DPB1 144–5, 153, 352, 354
HLA-DQ discrimination 112
HLA-DR 109-10
– -DQB typing 107–111
– subtyping 116
HLA-DRB determination 108, 115
HLA-DRB1 discrimintion 3, 4, 108
HLA-DRB1*04 17, 18
IDDM study 220–1
inefficiency 113
PCR-ASA 46–7, 50
Rg/Ch genotyping 328
TAP gene study 160–1
TGGE 314
see also left primers; right primers
probe
oligonucleotide 16, 17
Q-like gene (rat) 191, 192
promoter region variant nomenclature 485–517
proteinuria, and DR2 13
Provinces Françaises *see* PF
pseudogene amplification 199–200

Q/TL region (mouse) 189
Qui family 24–5

RA (rheumatoid arthritis) 91, 92
HLA-DP polymorphism 93–6
HLA-DPB1 distribution 93–4
HLA-DR/DPB1 linkage disequilibrium 93–6
HLA-DR3 296
HLA-DRB1*04 20
Lp(a) level 309–10
T cell δ polymorphism 479–83
TAP study 160
TNF 378–81
TNF Nco-I 461–7
TNFα 461–7
rat
MHC 189, 190
TAP polymorphism 166
ReA (reactive arthritis) 82, 88
and B27 88–9
HSP70 polymorphism 86
recombination
and BoLA class II 282
HLA-DR 36–40
paternal/maternal 38, 40
sex-linked 41
recombination assignment, accuracy 42
recombination fractions 35, 36
red blood cell typing, BoLA class I 243
relative predispositional effect 405–14
renal transplantation
HLA-DR antigens 447-8
PCR-SSP technique 113, 122
restriction patterns
4AOHW panel 362
HLA-DR, -DQB 117, 118–19
RFLP 106, 192, 194
BoLA class II 261–2
C4 343–45
CYP21 gene 343–45
HLA-DQ typing 392–3
TNF NcoI, and RA 461–7

PCR-SSP concordance 122, 447–55
Rg blood group 325
typing 330–35
Rg1/Ch1 typing 328–9
Rg3/Ch6 typing 328–9
rheumatoid arthritis *see* RA
ribonuclease protection assay 191–2
right primers 46, 48–9
mRNA 137–8
Rodgers blood group *see* Rg
RT(2.1) 192
CT sequence 194
sequencing 194
tertiary structure 195
RT(6.8) 191, 192
class-I molecule comparison 195
mapping region 194
sequencing 194–5
transcriptional activity 195–6
RT1. × loci 189
Rønningen model 226

Sanguinus oedipus
DRA1 sequence 73
DRB sequence 67–9
DRB1 sequence 69, 74–6
DRQB1/DRQB2 sequence 69, 70–2
segregation studies, TAP gene survey 165
selection, and mutation 397
sense/antisense strand identification 4–5
serological matching 106
DNA/serological typing comparison 200–3
HLA-DP polymorphism 144
limitations 210, 286
serology
BoLA
– class I 240–2, 243–9
– class II 260–1, 263–4
– difficulties 286
DNA typing/serology, for Rg/Ch typing 337
HLA, limitation of 210
serum W2245 173, 175, 176, 178
sex-linked HLA-DR gene frequencies
and cytokine increase 305–6
and Lp(a) levels 305–6
sex-linked recombination 41
single-strand conformation polymorphism 1–2
SLE (systemic lupus erythematosus) 11
ethnic suceptibility 12–13
genetic susceptiblity, Kuwaiti 300
HLA antigens 12–13
and TNF 379
Southern blot analysis *see* blot analysis
SPAFAS-11 line chickens 60, 61–2
speciation, and MHC polymorphism 393–4
spleen cell typing, HLA-DQB1 447–55
staining, HLA-DR2 DRB gene analysis 8
statistical tests, HLA-DP Swiss sample 147
surgery, and MBP 128
susceptibility markers, IDDM 225
Swiss, DPB1 oligotyping 144–55
synovial fluid, in RA 461–7
systemic lupus erythematosus *see* SLE
T cell receptor delta locus
A4-A5 genotype 479–83
and RA 479–83
T cell response, and TAP gene 160
T cells, in atherogenesis 308–9
T helper cells 391
TAP genes 159–66; *see also* linkage disequlibrium
TAP polymorphism 160
rat 166
TAP1, –2 gene frequency 161–2
TAP2 ambiguities, family pedigree 162
TAP2H allele 164
temperature gradient gel electrophoresis *see* TGGE
Tenascin B gene 349
TGGE (temperature gradient gel electrophoresis) 314–23
crossmatch analysis 317–19, 322
HLA-DR
– allele differentiation 319–22
– fingerprinting 317
– homoduplex patterns 315–16
Th × type cell response 310
thromboembolism 302
TL region (mouse) 189
TNF (tumor necrosis factor)
α, and RA 461–7
autoimmune disease 377–81
β 378–81
Todd model 223
transplantation
allelic matching 105–6
bone-marrow 105, 313
– HLA-DR TGGE analysis 317–19
– TGGE donor matching 322–3
HLA class II typing 2
HLA-A-B-DRB1/DPB1 disequilibrium 153–4
HLA-DR antigens 447–8
– DRB1*04 20
MHC animal studies 210
typing, PCR-SSP technique advantages 113, 122
transporter proteins 159
trypanosome infection, and class-I phenotype 212
tumor necrosis factor *see* TNF
tumorcidals 231
tumour, genetic control of resistance 60
21-hydroxylase 341
and CYP21 348
gene for 342
typing
DNA contamination 203
DNA/protein discrepancies 415–23
HLA-DR rapid 45–57
low-resolution DNA, nomenclature 485–517
typing ambiguities, HLA-DRB 55–6
typing error 106

vaccine, and MHC studies 209–10

W6/32, IEF results 249–51